Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tobacco use disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    83 result(s) found for: Tobacco use disorder. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2007-007020-18 Sponsor Protocol Number: 1999/07 Start Date*: 2008-05-26
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Efficacy of baclofen in the treatment of nicotine addicted patients:randomized, double blind study of Baclofen versus placebo
    Medical condition: Smoking addiction
    Disease: Version SOC Term Classification Code Term Level
    12.0 10043903 Tobacco abuse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002492-11 Sponsor Protocol Number: PRECESTO Start Date*: 2023-09-13
    Sponsor Name:NFL BIOSCIENCES SA
    Full Title: Phase II Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes
    Medical condition: Tobacco addiction
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004869 10043905 Tobacco use HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005138-21 Sponsor Protocol Number: TC-5619-23-CRD-003 Start Date*: 2012-04-03
    Sponsor Name:Targacept Inc.
    Full Title: A double-blind, placebo-controlled, multicenter, parallel group study to assess efficacy, safety and tolerability of TC-5619 as augmentation therapy to improve negative symptoms and cognition in ou...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000576-38 Sponsor Protocol Number: CARL Start Date*: 2022-06-08
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI CAMERINO
    Full Title: Effect of treatment of the cholinergic precursor Choline Alfoscerate in mild cognitive dysfunction
    Medical condition: Mild cognitive dysfunction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-009074-27 Sponsor Protocol Number: ACE-INIBITORE Start Date*: 2009-03-15
    Sponsor Name:PROF. ALFREDO CHETTA
    Full Title: Effect of an ACE inhibitor on the exercise capacity of COPD patients. A randomized double-blind placebo-controlled study
    Medical condition: PATIENTS AFFECTED BY COPD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038738 SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005857-23 Sponsor Protocol Number: MC/PR/033011/003/05 Start Date*: 2006-05-08
    Sponsor Name:CHIESI
    Full Title: DOUBLE BLIND, DOUBLE DUMMY, RANDOMISED, PARALLEL GROUP, MONOCENTRIC CLINICAL TRIAL ON THE EFFECTS OF CHF 1535 MDI OR SERETIDE DPI ON LUNG HYPERINFLATION AND EXERCISE TOLERANCE IN PATIENTS WITH COPD...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    6.1 10053420 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021217-23 Sponsor Protocol Number: D3550C00002 Start Date*: 2010-10-22
    Sponsor Name:AstraZeneca AB
    Full Title: A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients with Moderate...
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-003049-13 Sponsor Protocol Number: 7347 Start Date*: 2022-08-24
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: EEG-MRI study of the effect of methylphenidate on neural mechanisms in adult patients with ADHD with or without mood disorders: A randomized controlled trial versus placebo.
    Medical condition: Attention Deficit Hyperactivity Disorder (ADHD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002563-23 Sponsor Protocol Number: CD-RI-MEDI8968-1103 Start Date*: 2012-03-15
    Sponsor Name:MedImmune Limited
    Full Title: A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) LV (Completed) CZ (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000361-36 Sponsor Protocol Number: 12/0278 Start Date*: 2013-11-12
    Sponsor Name:Joint Research Office
    Full Title: A phase IIa/b, randomised, double-blind, placebo-controlled, single-site, parallel group clinical trial to examine cannabidiol (CBD) as a pharmacological treatment for cannabis dependence in a youn...
    Medical condition: 'Moderate cannabis use disorder' as defined by the diagnostic criteria in DSM-5 (published in May 2013), similar to the previous term 'cannabis dependence' (DSM-4).
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10007177 Cannabis dependence LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002380-26 Sponsor Protocol Number: Somagel Start Date*: 2018-09-13
    Sponsor Name:SOCIETÀ ITALO BRITANNICA L. MANETTI - H. ROBERTS & C. PER AZIONI
    Full Title: Single-group, open study on the systemic bioavailability, safety and local tolerability of a new gel formulation of Somatoline¿ in 30 healthy women.
    Medical condition: Edematous fibrosclerotic panniculopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001524-38 Sponsor Protocol Number: M/40464/30 Start Date*: 2011-09-23
    Sponsor Name:ALMIRALL, S. A.
    Full Title: EFFICACY AND SAFETY OF ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE FIXED-DOSE COMBINATIONS COMPARED WITH INDIVIDUAL COMPONENTS AND PLACEBO WHEN ADMINISTERED TO PATIENTS WITH STABLE CHRONIC OBSTRUCTIVE P...
    Medical condition: Chronic Obstructive Pulmonary Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) SK (Completed) HU (Completed) CZ (Completed) ES (Completed) FI (Completed) BE (Completed) DE (Completed) AT (Completed) DK (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000727-26 Sponsor Protocol Number: HZC111348 Start Date*: 2008-07-15
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study HZC111348, a repeat-dose study of GW685698/GW642444 Inhalation Powder versus placebo in the treatment of Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001363-67 Sponsor Protocol Number: D5241C00001 Start Date*: 2019-10-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstru...
    Medical condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed) FR (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-001396-30 Sponsor Protocol Number: A7881010 Start Date*: 2008-09-26
    Sponsor Name:Pfizer Ltd, Ramsgate Road, Sandwich, Kent, UK
    Full Title: A PHASE 2A, DOUBLE BLIND (3RD PARTY OPEN), 4 WAY CROSS-OVER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, TOLERATION AND EFFICACY OF SINGLE INHALED DOSES OF PF-00610355 IN ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003713-32 Sponsor Protocol Number: A5641009 Start Date*: 2005-11-29
    Sponsor Name:Pfizer Ltd
    Full Title: A phase II, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of UK-500,001 Dry Powder for Inhalation (DPI) in adults with moderate to severe Ch...
    Medical condition: Chronic obstructive pulmonary disease (COPD).
    Disease: Version SOC Term Classification Code Term Level
    10009033
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) ES (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010170-38 Sponsor Protocol Number: CSPP100G2301 Start Date*: 2010-07-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO)
    Medical condition: cardiovacular disease, fonctional hypertension,
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020772 Hypertension LLT
    12.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) DE (Completed) IE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005101-39 Sponsor Protocol Number: M/34273/30 Start Date*: 2008-08-19
    Sponsor Name:Laboratorios Almirall, S.A.
    Full Title: A 52-WEEK RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED, MULTICENTRE CLINICAL TRIAL, TO ASSESS THE EFFICACY AND SAFETY OF 200 μg OF THE ANTICHOLINERGIC LAS 34273 COMPARED TO PLACEBO,...
    Medical condition: Maintenance treatment of patients with moderate to severe stable chronic obstructive pulmonary disorder.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) DK (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000102-28 Sponsor Protocol Number: AFJ2020-1 Start Date*: 2020-08-19
    Sponsor Name:Mental Healt Center Copenhagen
    Full Title: Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration in glycaemic control in prediabetic or diabetic patients with schizophrenia spectrum disorder treated with the an...
    Medical condition: Schizophrenia spectrum disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10052792 Schizophrenia, undifferentiated type LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021638-72 Sponsor Protocol Number: HZC113782 Start Date*: 2011-06-09
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: HZC113782: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmo...
    Medical condition: Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) LV (Completed) AT (Completed) DE (Completed) GB (Completed) DK (Prematurely Ended) PL (Completed) GR (Completed) BG (Completed) ES (Completed) IT (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 19:58:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA